|Bid||13.52 x 800|
|Ask||13.59 x 2200|
|Day's Range||13.32 - 13.73|
|52 Week Range||13.32 - 34.99|
|Beta (5Y Monthly)||0.81|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||30.94|
Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No 596/2014PLANEGG/MUNICH, GERMANY / ACCESSWIRE / July 26, 2021 / MorphoSys AG (FSE:MOR; NASDAQ:MOR) announces today an update of its financial guidance for 2021 after preliminary completion of the latest evaluation of MorphoSys' half year 2021 financial performance.
PLANEGG, GERMANY and MUNICH, GERMANY / ACCESSWIRE / July 21, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR), a commercial-stage biopharmaceutical company and a leader in antibody and protein technologies, will publish its results for the second quarter and first half 2021 on July 28, 2021 at 10:00pm CEST (4:00pm EDT).MorphoSys' Management Board will host a conference call and webcast on July 29, 2021 at 2:00pm CEST (8:00am EDT) to present the second quarter and first half financial results 2021 and p
The new ordinary shares represent 3.9% of the registered share capital of MorphoSys following the capital increase.